Larimar Therapeutics, based in the Philadelphia area, is a publicly held company (NASDAQ: LRMR) and is committed to discovering and developing treatments for complex rare diseases, with an initial focus on Friedreich’s ataxia. Its proprietary protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that currently have ineffective or no treatments available.

Surgical Reconstruction CompanyStart-up Development stage

Member of the management team that sold the Company in June 2011 to Stryker Corporation for $316.0 million. Since acquisiton, serving on divisional leadership team with strategic financial planning, integration and reporting responsibilities for this new business unit within Stryker.Prior to acquisition, led all aspects of SEC reporting, internal reporting budgeting and forecasting, risk management, cost accounting and accounting operations for this biomaterials company with $100.0 million in sales revenue. •Developed forecasting model (Income Statement, Balance Sheet and Cash Flow) providing key performance indicator projections. •Managed strategic facilities expansion project saving $1.8 million in lab expansion costs and development of the Company’s 5- year strategic Facility plan.•Managed 2010 insurance renewal process resulting in a 25% savings ($300,000) compared to 2009 with significant increases in business interruption and contingent business interruption coverage.•Directed 15 accounting professionals.

Member of the executive management team charged with raising capital and developing and executing business strategy. Managed monthly GAAP financial reporting, annual audits, budgeting, forecasting and internal controls, managed all aspects of human resources, including recruiting, retention, compensation and employment practices.

Member of the founding management team responsible for building corporate and R&D infrastructure and developing two lead products. Managed monthly GAAP financial reporting, annual audits, budgeting, forecasting and internal controls, managed all aspects of human resources, including recruiting, retention, compensation and employment practices. Within 18 months of start-up, the Company was acquired by Human Genome Sciences, Inc.

Member of the financial group charged with managing strategic acquisitions and organic growth (2X increase in annualized revenues within 2 years of the Company’s IPO to $166.0M). Responsible for all aspects of the Company’s SEC reporting and internal reporting as well as shared services administration.

Member of finance department of this 6,500 person inbound and outbound telemarketing company, with annual revenues of $200.0M formed through the concurrent acquisition of six teleservice industry companies, and the completion of the Company’s Initial Public Offering of $162.0M. Recruited and managed 24 accounting professionals. Responsible for all aspects of an accounting infrastructure, integration and consolidation of acquired businesses.

Member of the senior management team responsible for the development of the Company’s CD4/CD8 diagnostic product, the preclinical development of sustained-release chemotherapeutics and ultimately the sale of the Company to CytRx, Inc. (NASDAQ:CYTR). Responsible for all aspects of the Company’s SEC reporting and internal reporting

Member of the finance department of this publicly-held biopharmaceutical Company. (NASDAQ: CNTO) Responsible for external and internal financial reporting, forecasting and technical accounting research including inventory accounting and revenue recognition.

Client assignments included two of the firm’s three largest Philadelphia based clients. Extensive SEC experience.